Naxitamab and GM-CSF in Combination With IT in Patients With High-Risk Neuroblastoma

NCT04560166 PHASE2 TERMINATED Results posted

An International, Single-Arm, Multicenter Phase 2 Trial.

Details

Lead sponsor	Y-mAbs Therapeutics
Phase	PHASE2
Status	TERMINATED
Enrolment	2
Start date	Mon Nov 08 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed Sep 21 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Neuroblastoma Recurrent

Interventions

• Naxitamab and GM-CSF in combination with irinotecan and temozolomide

Countries

Hong Kong, South Korea